Does Pennsylvania Medicaid cover GLP-1s for weight loss?
Does Pennsylvania Medicaid cover GLP-1s for weight loss?
Pennsylvania Medicaid covers a weight-loss drug but not a GLP-1 on that indication. Coverage for type 2 diabetes, for Wegovy's cardiovascular indication and for Zepbound in moderate to severe sleep apnea is required of every state program regardless. So the practical question at a denial is rarely "does my state cover it" but "which indication am I being prescribed this under". The status is read from the state's own document, Pennsylvania DHS Medical Assistance Bulletin of 24 November 2025: GLP-1 receptor agonists and obesity treatment agents, rather than from a national summary. The exclusion is permitted rather than required. Section 1927(d)(2) of the Social Security Act lets a state Medicaid program leave out drugs used for weight loss, so this is a state decision, not a fact about the drug. Where the answer is no, the cheapest verified cash route on this site is $129 a month (compounded, not FDA approved; FDA warning letter). Last checked 2026-09-13.
What Pennsylvania changed, and when
- 2026-01-01 — GLP-1s for obesity eliminated; other weight-loss drugs stay the document that says so
From 1 January 2026 no drug containing a GLP-1 is covered for overweight or obesity; obesity drugs without a GLP-1, such as phentermine, stay covered, and GLP-1s remain covered with prior authorization for other medically accepted indications.
Whatever Pennsylvania decides about obesity, federal law still makes it cover a GLP-1 prescribed for type 2 diabetes, Wegovy for cardiovascular risk reduction and Zepbound for obstructive sleep apnea — the exclusion is written against the use, not the drug. Which approval a weight-loss exclusion cannot reach, and what each label says.
If you end up paying cash
The cheapest verified GLP-1 routes — what you pay per month once titrated, not an introductory rate:
- Strut Health$129/moverified 2026-09-22compounded, not FDA approvedFDA warning letter
- Noom Med$249/moverified 2026-09-22compounded, not FDA approved
- Found$289/moverified 2026-09-22compounded, not FDA approved
Cheaper still, and a different class: Qsymia (phentermine/topiramate) at $75/mo — about 9.8% mean weight loss in its trial, against roughly 15 to 21% for the GLP-1s above. It is a real option and it is not a substitute.
The manufacturer programs cut the first fills further, and each one's catch is printed with it. Write the appeal first if you were refused — it costs nothing and the criteria above are what it has to answer.
Other states with criteria of their own
Source: Pennsylvania DHS Medical Assistance Bulletin of 24 November 2025: GLP-1 receptor agonists and obesity treatment agents , effective 2026-01-01. Read on 2026-09-13. Fee-for-service rules; a managed-care plan in Pennsylvania can publish its own formulary and step edits. This is a record of what the payer publishes, not medical or legal advice.